Importantly, empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor frequently used to treat type 2 diabetes, has successfully resolved neutrophil defects in patients with G6PC3 deficiency by lowering the 1,5-AG blood concentrations [47, 60, 61]. Here, SLC5A2 is linked to type 2 diabetes mellitus.